Silence Therapeutics Reports Topline Results From Phase 1 Multiple Dose Study Of Zerlasiran; Lp(a) Levels Remained Around 90% Lower Than Baseline At Study Endpoint
Portfolio Pulse from Benzinga Newsdesk
Silence Therapeutics has reported topline results from its Phase 1 multiple dose study of Zerlasiran. The study found that Lp(a) levels remained around 90% lower than baseline at the study endpoint.
November 01, 2023 | 11:12 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Silence Therapeutics' positive Phase 1 results for Zerlasiran could potentially boost investor confidence and have a positive impact on its stock price.
Positive clinical trial results often lead to increased investor confidence, which can drive up a company's stock price. Given that the results for Zerlasiran were positive, this could potentially have a positive impact on Silence Therapeutics' stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100